secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2022-08-12T23:59:59+00:00
Accession:  0001683168-22-005590
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study
--------------------------------------------------------------------------------

- Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.
- Cash balance of $14.9M at quarter end; royalty payments from Takeda sublicensee ~$0.4M (+45% YoY).
- In-licensed DNase-based oncology platform from CLS Therapeutics in April 2022; targeting Phase 1 in pancreatic carcinoma.
- Engaged Catalent for cGMP manufacturing of Phase 1 clinical supply; collaboration with Belgian Volition for NETs-targeted cell therapies.
- Bolstered IP with U.S. patent for XCART platform covering co-administration of CAR T cells with personalized vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822005590/0001683168-22-005590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822005590/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer